TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Leqembi and Kisunla are FDA-approved anti-amyloid antibodies for people with early Alzheimer’s in the United States. Trials found that both drugs reduced brain amyloid and modestly slowed decline, but neither restores lost memory or cures the disease; the size of the everyday benefit and the long-term balance of benefits and risks remain under discussion.
Two FDA-approved Alzheimer’s drugs, Leqembi (lecanemab) and Kisunla (donanemab), target different forms of the beta-amyloid protein that builds up in the brain. Clinical trials found that both reduced amyloid and modestly slowed cognitive and functional decline in people with early Alzheimer’s, but they do not cure the disease or recover memory already lost. The scale of benefit in daily life and how it compares with treatment risks remain debated.
Both medicines are monoclonal antibodies: laboratory-made proteins designed to bind to specific targets. In Alzheimer’s, they attach to beta-amyloid and help the immune system clear it from the brain. Amyloid can form plaques between brain cells, though researchers continue to study how different forms of the protein relate to cognitive decline.
The drugs bind to different amyloid forms. Leqembi binds to plaques and smaller aggregates called protofibrils. Kisunla primarily targets a modified form of beta-amyloid present in established plaques. The U.S. Food and Drug Administration approved Leqembi in July 2023 and Kisunla about a year later, according to the source report.
In Leqembi’s phase 3 trial, participants taking the drug declined about 27 percent more slowly over 18 months than participants given placebo. In Kisunla’s phase 3 trial, the overall study population had a 37 percent lower risk of progressing to the next clinical stage over 76 weeks than the placebo group. These figures come from separate trials with different measures and time frames, so they should not be treated as a direct comparison between the drugs.
What Amyloid Removal Can—and Cannot—Do
The treatments mark a shift from managing Alzheimer’s symptoms alone toward targeting a feature of the disease’s underlying biology. For some people with early disease, slowing decline may affect how long they retain abilities, but trial results do not mean patients improve or experience the same outcome.
The clinical importance of the measured changes remains contested. An April 2026 Cochrane review, which pooled 17 trials involving more than 20,000 participants, concluded that average cognitive and functional benefits of anti-amyloid antibodies were too small to be clinically meaningful and that treatment increased the risk of brain swelling and bleeding. The review covered multiple antibodies, not just the two newer drugs. Some Alzheimer’s specialists challenged its interpretation, arguing that it grouped newer treatments with older antibodies that did not substantially clear amyloid.
The disagreement matters to patients and families weighing a treatment that requires careful consideration of potential benefit and harm. Clearing amyloid is a biological effect; how directly that translates into a noticeable difference in everyday life is not settled.
Alzheimer's anti-amyloid monoclonal antibody medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Two Drugs, Distinct Amyloid Targets
Beta-amyloid accumulation is one of the brain changes associated with Alzheimer’s, but it is not the only feature of the disease. Scientists are still working to establish how plaque, smaller protein aggregates and other disease processes contribute to symptoms. The antibodies are therefore aimed at a specific biological target, rather than treating every cause of Alzheimer’s or reversing existing damage.
Both drugs were studied and approved for people in the earliest symptomatic stages of Alzheimer’s, making early identification relevant to treatment decisions. The source report also describes real-world evidence, including an Eisai-funded study of 177 people who had taken Leqembi for a year: 77 percent had not progressed to the next disease stage and 7 percent had moved from early Alzheimer’s to mild cognitive impairment. Because that study had no placebo group, it cannot establish how much of the observed stability was due to the drug.
Researchers cited in the report caution that Alzheimer’s progresses slowly and treatment effects are modest, so one or two years of follow-up may not resolve questions about long-term impact.
“Existing approved drugs offer some benefit for some patients, but there remains a high unmet need for more effective treatments.”
— Edo Richard, professor of neurology at Radboud University Medical Centre and senior author of the Cochrane review, as quoted in a press release
How Much Benefit Patients Experience
It remains unclear how much the trial-measured slowing changes daily life for an individual patient and how durable the effect is over longer periods. The source report says newer research suggests greater amyloid clearance does not necessarily mean greater slowing of cognitive decline.
Longer-term real-world evidence is still developing. The one-year Leqembi study lacked a placebo comparison, so its reported stability cannot show what would have happened to the same patients without treatment. Treatment risks also matter: the Cochrane review reported increased risk of brain swelling and bleeding, but the provided source does not give individual risk estimates or explain how risks vary across patients.
The report does not provide a full account of eligibility rules, monitoring schedules or how clinicians select between the two drugs. Those details should not be inferred from the trial results alone.
Longer Follow-Up and Patient Selection
Researchers are expected to keep examining real-world outcomes and longer-term effects, including whether the modest changes seen in trials translate into sustained differences in function. The report notes that evidence presented in 2026 continued to suggest many patients remain stable while receiving treatment, while also cautioning that short follow-up makes the drugs’ lasting impact difficult to measure.
For now, the findings apply to people with early symptomatic Alzheimer’s who meet treatment criteria, not to everyone with memory problems or later-stage disease. Patients considering either antibody need an individualized discussion with a qualified clinician about likely benefits, treatment risks, eligibility and monitoring. The available evidence does not settle which drug is preferable for a particular patient.
Key Questions
How do Leqembi and Kisunla work?
They are monoclonal antibodies that bind to beta-amyloid and help the immune system clear it from the brain. Leqembi binds to plaques and smaller aggregates called protofibrils; Kisunla primarily targets a modified form found in established plaques.
Do the drugs cure Alzheimer’s or restore lost memory?
No. The source report says neither drug cures Alzheimer’s or restores memory that has already been lost. Trial evidence indicates that they can modestly slow cognitive and functional decline in people with early disease.
Are Leqembi and Kisunla equally effective?
The figures in the report come from separate trials using different outcome measures and time frames. They do not establish a direct comparison, so they cannot show that one drug is more effective than the other.
What are the main concerns about treatment?
The Cochrane review cited in the report found increased risks of brain swelling and bleeding and judged the average benefits across the trials it reviewed too small to be clinically meaningful. Some specialists disputed its conclusions, particularly its grouping of newer drugs with older antibodies. Patients should discuss individual risks and possible benefits with a qualified clinician.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
